Ask AI
ProCE Banner Activity

Implementing Systemic Therapy in H3 K27–Altered DMG: Practical Strategies to Optimize Post-Radiation Care

Slideset

Downloadable slides on the diagnosis and management of H3 K27–altered diffuse midline glioma (DMG), including molecular testing strategies, clinical characteristics, and emerging treatment approaches. The slides review clinical efficacy and safety data supporting dordaviprone for recurrent H3 K27M–mutant DMG following prior therapy, its mechanism of action, and practical considerations for treatment initiation, dosing, adverse event management, QTc monitoring, and drug interactions. Evidence from ongoing studies of targeted therapies, CAR T-cell therapies, oncolytic viruses, and other investigational approaches is also highlighted, along with strategies for postradiation treatment sequencing, clinical trial referral, and multidisciplinary care coordination to support individualized treatment decisions in pediatric and adult patients.

Released: November 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for neuro-oncologists and other healthcare professionals who care for patients with diffuse midline glioma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular testing pathways to confirm H3 K27 status and document eligibility decisions at diagnosis and progression

  • Interpret the latest efficacy, safety, and regulatory data supporting protease activator therapy in recurrent DMG following radiation to inform evidence-based care decisions

  • Implement a post-RT sequencing algorithm integrating symptoms, steroid trajectory, imaging interpretation, and trial referral ready monitoring workflow (QTc risk screening/monitoring, symptom triage, escalation thresholds) in pediatric and adult settings

  • Identify patients for biomarker-driven clinical trials investigating novel targeted therapies and combination strategies in DMG, including earlier-line settings where clinically appropriate